FDA's Crawford charged with lying about stock
The mystery that surrounded the sudden and unexplained departure of Lester Crawford shortly after his confirmation as FDA chief has cleared up. Crawford was charged yesterday with lying about the stocks he owned in companies regulated by the agency. Specifically, Crawford owned stock in Pepsi and Sysco at a time he chaired the FDA's Obesity Working Group, which made decisions about snack and soft drink products. And he had owned stock and been a member of the board of Embrex, an agricultural biotech company regulated by the FDA. The criminal charges brought by the Justice Department allege that Crawford lied about the shares, saying they had been sold. Crawford's attorney says he will plead guilty today to two misdemeanors: false writing and conflict of interest. Each charge carries a potential one-year jail sentence.
- here's the AP report on the charges
- and here's a report on the plea deal
Related Articles:
FDA's Crawford faces criminal investigation. Report
Crawford acknowledges role nixing Plan B. Report
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

